Your fact-checks will appear here
Nonprofit organization
Bill Gates has made personal investments aimed at Alzheimer’s research totaling about $100 million — a $50 million check to the Dementia Discovery Fund (DDF) and roughly $50 million pledged for start‑...
Bacopa monnieri can alter drug metabolism via inhibition of several cytochrome P450 enzymes (notably CYP3A4, CYP2C9 and CYP2C19) and may therefore raise or lower blood levels of drugs processed by tho...
Clinical research testing honey or cinnamon specifically for cognitive decline in adults is extremely limited: systematic reviews identify two small human cinnamon studies (one positive in adolescents...
Bill Gates has put at least $100 million of personal money into Alzheimer’s-related efforts: a $50 million pledge to the UK-based Dementia Discovery Fund in 2017 plus another $50 million he said would...
Available clinical reviews and trials find no clear evidence that stopping Bacopa monnieri causes a defined withdrawal syndrome or persistent cognitive decline; clinical reports describe it as general...
Venture capital is often absent where commercial returns are unclear, and the reporting shows that in dementia research those gaps most frequently align with social-science, prevention/implementation ...
A systematic review identified five randomized controlled trials (RCTs) that tested in people with Alzheimer’s disease (AD) or mild cognitive impairment () attributable to AD, with wide variation in f...
Randomized controlled trials specifically testing honey for mild cognitive impairment (MCI) or Alzheimer’s disease do not exist in the published literature . Cinnamon has been evaluated in a tiny clin...
Bill Gates personally committed roughly $100 million to Alzheimer’s and dementia efforts beginning in 2017, and the bulk of that money has gone to drug discovery, diagnostics and venture-style investm...
A small, investigator‑initiated Phase I ALS safety trial and at least one registered Phase IIa trial for early‑stage Alzheimer’s disease / mild cognitive impairment are recorded in the public literatu...
Yes — Bill Gates (through Gates Ventures and personal initiatives) and allied philanthropic investments have funded biomarker research and programs that support clinical trials in Alzheimer’s disease,...
Bill Gates has been an active funder of major Alzheimer’s and dementia initiatives since 2010, but much of that money has come from his personal wealth and Gates Ventures rather than directly from the...
Dr. Dean Ornish’s peer‑reviewed Alzheimer’s trial, published June 7, 2024 in Alzheimer’s Research and Therapy, reports that an intensive, drug‑free lifestyle intervention produced statistically signif...
Dr. Sanjay Gupta is best known in the Alzheimer’s conversation as CNN’s chief medical correspondent and a practicing neurosurgeon who has produced reporting and a documentary series on Alzheimer’s dis...
Randomized clinical trials of phosphatidylserine (PS) in older adults exist but are few, small, and heterogeneous: early trials using bovine-cortex PS reported short-term cognitive benefits in age-ass...
Two registered, investigator-led clinical programs are testing oral L‑serine in people with neurodegenerative disease: an ongoing Phase II randomized trial of L‑serine in early-stage Alzheimer’s disea...
Since the FDA’s 2003 consumer alert and restrictions around bovine-derived phosphatidylserine, the clinical literature has continued with randomized trials and at least one modern systematic review/me...
Private philanthropy has seeded and accelerated multiple Alzheimer’s breakthroughs: venture-philanthropy groups like the Alzheimer’s Drug Discovery Foundation (ADDF) invest in early therapeutics and e...
Dr. Sanjay Gupta in 2024–2025 is prominently reporting and speaking about Alzheimer’s research — focusing on lifestyle interventions, prevention and early detection — rather than running a lab or publ...
Clinical trials and systematic reviews most often use standardized Bacopa monnieri extracts at 300–600 mg daily and report cognitive benefits emerging after about 8–12 weeks of continuous use (example...